Watch Demo

Drug Overview: Risperdal Consta

Drug Overview: Risperdal Consta

  • Publish Date:April 2018

  • Number of Pages:26

  • Report ID:5391511

  • Format:PDF

  • Publisher:Datamonitor Healthcare

$ 10000

Summary

Drug Overview 
Risperdal Consta (Johnson&Johnson) contains risperidone, an atypical antipsychotic that acts as a selective dopamine and serotonin receptor antagonist that also blocks the dopamine D2, serotonin (5-HT2), and alpha-2 adrenergic receptors. Risperdal Consta is the long-acting injectable formulation of Johnson&Johnson’s oral drug Risperdal. 

Risperdal was initially approved for bipolar disorder in the US in 2003. Johnson&Johnson later launched Risperdal Consta in the US in May 2009. In the following year, EU regulators denied Risperdal Consta approval for the treatment of bipolar disorder, which prompted Johnson&Johnson to abandon the development program in these markets. The drug is also approved for the treatment of schizophrenia.

Table of contents

TABLE OF CONTENTS

4 OVERVIEW
4 Drug Overview
5 Product Profiles
5 Risperdal Consta : Bipolar disorder
16 Risperdal Consta : Schizophrenia

LIST OF FIGURES
11 Figure 1: Risperdal Consta for bipolar disorder - SWOT analysis
12 Figure 2: Datamonitor Healthcare's drug assessment summary for Risperdal Consta in bipolar disorder
13 Figure 3: Datamonitor Healthcare's drug assessment summary for Risperdal Consta in bipolar disorder
19 Figure 4: Risperdal Consta for schizophrenia - SWOT analysis
20 Figure 5: Datamonitor Healthcare's drug assessment summary of Risperdal Consta for schizophrenia
21 Figure 6: Datamonitor Healthcare's drug assessment summary of Risperdal Consta for schizophrenia
23 Figure 7: Risperdal Consta sales for schizophrenia across the US, Japan, and five major EU markets, by country, 2017-26

LIST OF TABLES
5 Table 1: Risperdal Consta bipolar disorder indication approvals
6 Table 2: Risperdal Consta drug profile
8 Table 3: Risperdal Consta pivotal trial data in bipolar disorder
10 Table 4: Adverse reactions in ?5% of Risperdal Consta-treated adult patients with bipolar disorder
16 Table 5: Risperdal Consta drug profile
18 Table 6: Risperdal Consta pivotal trial data in schizophrenia
24 Table 7: Risperdal Consta sales for schizophrenia across the US, Japan, and five major EU markets, by country ($m), 2017-26

Methodology

Our market research methodology is designed to provide the clients with comprehensive and accurate information on various industries and markets. It includes data collection, primary interviews, macro-economic factor analysis, country-level data analysis etc.

The data is gathered from a wide range of sources, including industry reports, government statistics, and company financials. This data is then analyzed and cross-referenced to ensure its accuracy and reliability. Next, primary interviews are conducted with industry experts and key stakeholders to gather their insights and perspectives on the market. This information is then combined with the data collected to provide a complete picture of the market. Macro-economic factor analysis is also carried out to understand the impact of external factors on the market. Finally, country-level data analysis is performed to understand the market dynamics in specific regions and countries.

Reportlinker's market research methodology is designed to provide clients with a clear understanding of the market, its trends, and its future potential.